Artificial intelligence (AI) innovation has been growing at a rapid pace and the ability to discover new “drug-like” and synthetically viable compounds via AI is of great interest to medicinal chemists. A key challenge in using AI for drug discovery is the lack of robust machine learning (ML) models trained on experimentally proven data. MilliporeSigma turned to C&EN Media Group on how they could effectively demonstrate solving drug design challenges with validated AI/ML methods and computational tools with the AIDDISON™ integrated platform.

C&EN Media Group built a lead generation strategy around MilliporeSigma’s webinar titled “Unlock the Power of Artificial Intelligence in Novel Drug Discovery.”

Dr. Ashwini Ghogare, head of AI and Automation for Drug Discovery in the Global Science and Technology Group at Merck KGaA, showed attendees how the AIDDISON™ platform can unlock ingenuity for new molecule designs tailored to their needs with AI methods and computational tools and much more. Dr. Ghogare utilized two case studies to demonstrate to attendees how the AIDDISON™ platform can help users branch from known into novel chemical spaces and to optimize a new lead series.

By implementing a highly effective lead generation strategy for MilliporeSigma’s webinar campaign, C&EN Media Group was able to surpass MilliporeSigma’s guaranteed lead goal of 600 by over 103%. The results below demonstrate how C&EN Media Group created a robust pipeline of leads for MilliporeSigma.